Variable |
|
Median GTV (cc) (range) |
34.09
(1.00 - 258.12) |
Lesion Location
|
|
Nasopharynx |
15 patients (33.33%) |
Gum, floor of mouth, other mouth |
5 patients (11.11%) |
Tongue |
9 patients (20.00%) |
Oropharynx |
10 patients (22.22%) |
Pharynx/location not specified |
5 patients (11.11%) |
Hypopharynx |
1 patient (2.22%) |
Median prescribed dose (range) |
30 Gy (20 Gy - 42.5 Gy) |
Median time to locoregional failure (LRF) (months) (range) |
6.07 (1.5 - 59.43) |
Median OS (months) (range) |
9.23 (0.7 - 59.43) |
Median KPS after treatment (range) |
80% (10% - 100%) |
Patients with rise in KPS |
3 patients (14.29%) |
Patients with no change in KPS |
17 patients (80.95%) |
Patients with decline in KPS |
1 patient (4.76%) |
Median VAS pain score after treatment (range) |
0 (0 - 10) |
Patients with rise in VAS pain score |
3 patients (13.04%) |
Patients with no change in VAS pain score |
12 patients (52.17%) |
Patients with decline in VAS pain score |
8 patients (34.78%) |